Synthesis and immunosuppressive activity of new artemisinin derivatives.: 1.: [12(β or α)-dihydroartemisininoxylphen(ox)yl aliphatic acids and esters

被引:50
作者
Yang, ZS
Zhou, WL
Sui, Y
Wang, JX
Wu, JM
Zhou, Y
Zhang, Y
He, PL
Han, JY
Tang, W
Li, Y
Zuo, JP
机构
[1] Chinese Acad Sci, Dept Synthet Chem, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Dept Pharmacol 1, State Key Lab Drug Res, Shanghai Inst Mat Med,Inst Biol Sci,Grad Sch, Shanghai 201203, Peoples R China
关键词
D O I
10.1021/jm048979c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of novel dihydroartemisinin derivatives were synthesized and evaluated on their immunosuppressive activity in the search for potential immunosuppressive agents with high efficacy and low toxicity. These compounds were assayed in their cytotoxicity of lymphocyte, inhibition activity on concanavalin A (ConA) induced T cell proliferation and lipopolysaccharide (LPS) induced B cell proliferation. Among them, 11b, 13b, 14d, 15b, 16, and 17 remarkably exhibited lower cytotoxicity and higher inhibition activity on the mitogen-induced T cell and B cell proliferation in comparison with artemisinin, artesunate, and artemether in vitro. More significantly, compound 11b displayed reduced cytotoxicity by over 100-fold compared with cyclosporin A (CsA) and comparable inhibition activity (SI = 848) on ConA-induced T cell proliferation to CsA (SI = 963) and more than 4000 times the inhibitory effect (SI = 28473) on LPS-induced B cell proliferation compared with CsA (SI = 7) in vitro. The in vivo experimental results showed that compound 16 could inhibit 2,4-dinitrofluorobenzene (DNFB)-induced delayed-type hypersensitivity (DTH) reaction and sheep red blood cell (SRBC) induced antibody production, respectively. The structure and activity relationships (SAR) of these compounds were also discussed.
引用
收藏
页码:4608 / 4617
页数:10
相关论文
共 41 条
[1]   Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506 [J].
Ader, JL ;
Rostaing, L .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (05) :539-545
[2]   Immunosuppressive drugs, the first 50 years and a glance forward [J].
Allison, AC .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :63-83
[3]  
Arriola ER, 1999, WESTERN J MED, V170, P278
[4]  
Chen ZL, 2002, CHINESE J ORG CHEM, V22, P22
[5]  
[董妍君 Dong Yanjun], 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P676
[6]  
Dumont F J, 2001, Curr Opin Investig Drugs, V2, P357
[7]  
Feng YH, 2002, ACTA PHARMACOL SIN, V23, P893
[8]   Novel therapeutic agents for systemic lupus erythematosus [J].
Gescuk, BD ;
Davis, JC .
CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (05) :515-521
[9]   Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity [J].
Grabbe, S ;
Schwarz, T .
IMMUNOLOGY TODAY, 1998, 19 (01) :37-44
[10]  
GREENE JM, 1983, Patent No. 0089805